SCHEMBL543613

SCHEMBL543613

Cc1nc2cccc(C3CC3CN3C(=O)c4ccccc4C3=O)n2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.34
ALDH1A1 P00352 5/20 0.34
CYP2C19 P33261 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
KEAP1 Q14145 3/20 0.33
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
NFE2L2 Q16236 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
CYP2D6 P10635 1/20 0.33
JAK1 P23458 1/20 0.32
EGLN2 Q96KS0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543423 0.80 RXFP1 (0.42) RXFP1ALDH1A1CYP2C19CYP1A2CYP2C9
SCHEMBL544278 0.78 HTR2C (0.41) EGLN2
SCHEMBL544043 0.73 CYP1A2 (0.32) RXFP1ALDH1A1CYP2C19CYP1A2CYP2C9
SCHEMBL544308 0.71 PDE4A (0.38) ALDH1A1CYP1A2MAPTGAATSHR
SCHEMBL4743617 0.68 CYP1A2 (0.53) ALDH1A1CYP2C19CYP1A2CYP2C9HPGD
SCHEMBL543160 0.67 KEAP1 (0.37) RXFP1ALDH1A1CYP2C19CYP1A2CYP2C9
SCHEMBL543760 0.66 CREBBP (0.39) ALDH1A1CYP2C19CYP1A2CYP2C9KEAP1
SCHEMBL543761 0.66 CREBBP (0.39) ALDH1A1CYP2C19CYP1A2CYP2C9KEAP1
SCHEMBL14697184 0.65 SLC6A2 (0.49) ALDH1A1CYP2C19CYP1A2CYP2C9KMT2A
SCHEMBL20570123 0.65 CYP1A2 (0.41) ALDH1A1CYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 EP disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH RXFP1 208/4885ALDH1A1 1431/4885CYP2C19 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.